



## **Acura Pharmaceuticals to Present at the BioCentury NewsMakers in the Biotech Industry Conference**

Palatine, IL - (October 18, 2011) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today that the company is scheduled to present at the 18<sup>th</sup> Annual NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel in New York City on Friday, October 21. Bob Jones, Acura Pharmaceutical's Chief Executive Officer will provide a company overview at 3:00 PM Eastern Time.

During the presentation, material information concerning the Company, its operations, strategies and prospects may be discussed. A live webcast of the presentation will be available through the Investor page of Acura's website: [www.acurapharm.com](http://www.acurapharm.com). An archived version of the presentation will be available for 30 days after the event.

Utilizing its proprietary AVERSION® and IMPEDE™ technologies, Acura develops products intended to address medication abuse and misuse. AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nose.

IMPEDE is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

### **About Acura Pharmaceuticals**

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary AVERSION and IMPEDE technologies. In June 2011, the U.S. Food and Drug Administration approved the first product incorporating the AVERSION technology. The Company has a development pipeline of additional AVERSION technology products including other opioids, stimulants and benzodiazepines and its IMPEDE technology for pseudoephedrine hydrochloride products.

### **Contact:**

Stephanie Marks for Acura Investor Relations  
[smarks@lazarpartners.com](mailto:smarks@lazarpartners.com)  
212-843-0211

Rachel Kessler for Acura Media Relations  
[rkessler@lazarpartners.com](mailto:rkessler@lazarpartners.com)  
917-660-0608